Eliem Therapeutics is a clinical-stage biotechnology company.
Our focus is to advance the clinical development of assets for the treatment of hyperexcitability disorders, such as chronic pain. Patients desperately need access to safe, efficacious, and well-tolerated non-opioid therapies to remedy chronic pain. Drugs currently prescribed for pain relief have limited efficacy in addition to tolerability and safety issues, which severely limit their therapeutic benefit.
We will leverage our world-class expertise in neuroscience, translational medicine, and clinical development to address this unmet medical need with a highly innovative pipeline.
Eliem Therapeutics is pioneering a new generation of analgesics to facilitate a better quality of life for patients.
President and Chief Scientific Officer
Valerie Morisset, PhD is Co-Founder and Chief Scientific Officer of Eliem Therapeutics. Valerie has more than 20 years’ experience in the pharmaceutical industry, with positions of increasing responsibility at Novartis, GSK, Convergence, and Biogen. Prior to joining Eliem, Valerie was a founding venture partner at Bridge Valley Ventures. She co-founded Convergence Pharmaceuticals, where she established and led the Biology and Translational Medicine team, and was instrumental in the sale of Convergence to Biogen for $675M in 2015. Valerie subsequently joined Biogen in a senior leadership role. She has worked extensively in the field of drug development for Pain and across a number of other therapeutic areas including Neurology, Psychiatry, Gastrointestinal Disorders and Sensory Biology. Valerie trained as an electrophysiologist and completed her PhD at the University of Bordeaux.
Chief Development Officer
Jo Palmer-Phillips, PhD is Chief Development Officer at Eliem Therapeutics. Joanne is a neuropsychologist with over 18 years’ experience working in clinical development in the pharmaceutical industry with a focus on pain and migraine. She has held positions in both clinical operations and clinical strategy including leading multidisciplinary clinical teams at Roche, GSK, Convergence Pharmaceuticals and Biogen. She was a founding member of Convergence Pharmaceuticals Ltd and a member of the leadership team. As the Head of Clinical Operations at Convergence she was responsible for designing and managing the full-service outsourcing of phase 1 and 2 clinical studies in pain. She was also responsible for establishing and maintaining the Quality System.
Chief Medical Officer
Amy Chappell, M.D., has 32 years of CNS clinical drug development experience first at Eli Lilly and company (25.5 years), followed by extensive consulting for small and large pharmaceutical companies. Her most recent position was VP, Neuroscience, at PPD, a contract research organization. Amy has deep expertise in translational neuroscience and in all phases of clinical drug development across a wide range of neurological indications including epilepsy, ALS, Parkinson’s, Alzheimer’s, multiple pain types, migraine, and multiple sclerosis. She has interacted with multiple Regulatory Agencies and was the medical lead on the development and NDA submission of duloxetine for fibromyalgia which resulted in an FDA approval. She is the author of many peer-reviewed scientific publications.
Amy is certified by the American Board of Neurology and Psychiatry (neurology with special competency in child), the American Academy of Pediatrics (specialty certification), and by the American Board of Lifestyle Medicine. She has 40 years of clinical practice experience in child and adult neurology and holds active Florida and Indiana medical licenses.
She is a graduate of Antioch College (BS) and the Indiana University School of Medicine (MD). She completed her post-doctoral training at the Johns Hopkins Hospital (pediatric residency and epilepsy fellowship) and the Indiana University Medical Center (neurology residency).
Head of Operations
Helen Gaby is the Head of Operations at Eliem Therapeutics. Helen has over 20 years of experience working in the pharma industry including for SmithKine Beecham and GSK. She was a founder member of Convergence Pharmaceuticals, playing a key role in establishing policies and procedures and then managed the transfer of financial and operational matters to Biogen after the sale of Convergence to Biogen in 2015. She has a degree in Economics.
Head of Chemistry
David Witty, DPhil is Head of Chemistry – Research, Development and Manufacturing at Eliem Therapeutics. David is also a co-founder of Convergence and Witnet R&D Consultancy and has spent more than 25 years in Pharmaceutical R&D. He has led projects for GSK, Convergence, Biogen and Witnet in areas ranging from anti-infectives, metabolic diseases, cognition, cancer therapeutics and pain. David is the Senior Editor of Progress in Medicinal Chemistry and has published more than 100 primary papers, reviews, books and patents. He gained his first degrees and doctorate in Chemistry from Oxford University and is the recipient of the Royal Society of Chemistry BMCS Lectureship and a Board Member of SCI.
Head of Clinical Operations
David Mister, MS is Head of Clinical Operations at Eliem Therapeutics. David comes to Eliem with over 20 years of experience in Clinical Development related activities. He started his career as an in-house CRA at Cocensys, a small biopharmaceutical company developing compounds for various neurological disorders. After leaving Cocensys he worked for seven years in various monitoring and project management functions at two CROs, first CroMedica as one of their first US employees, and then PRA International as part of an acquisition. David has spent the last 15 years in several Clinical Development and Operations functions at Allergan in Irvine, California. He has a wide level of management experience working on all levels of the clinical development process from Phase I through III of the development process, through phase IV post-marketing activities. He is located in Orange Country, California.
Board of Directors
Managing Director, RA Capital Management, L.P. & Co-founder and Interim Chief Executive Officer
Andrew Levin, MD, PhD is Co-Founder and Interim Chief Executive Officer of Eliem Therapeutics. In addition to co-founding Eliem, Andrew spearheads drug discovery efforts at RA Capital Management, L.P. that have led to the formation of several companies and serves as a Managing Director on the Investment Team. Previously, Andrew was a Vice President at H.I.G. BioVentures, and prior to that served as the Director of Pharmaceutical Sciences for the Clinton Health Access Initiative. He holds a BSE in Mechanical Engineering from Princeton University, a PhD in Biomedical Engineering from the Massachusetts Institute of Technology, and an MD from Harvard Medical School.
Partner at Bridge Valley Ventures
Simon Tate, PhD is a partner at Bridge Valley Ventures and has 30 years of experience in R&D. Simon has spent most of his career working in the fields of Pain and Neuroscience. He was one of the founders of Convergence Pharmaceuticals, and as Chief Scientific Officer and head of R&D, led Convergence to its successful acquisition by Biogen for $675M in 2015. Following this acquisition, Simon joined Biogen where he assumed the role of Vice President and Head of the Pain Therapeutic Area. Prior to Convergence, Simon was Vice President and Head of Pain, Epilepsy, and Migraine drug discovery and early development in GSK, where he held senior roles in Neurology, Psychiatry, and Discovery Sciences during his 20-year career. Originally trained as a Biochemist, Simon graduated from the University of Dundee, where he had the privilege to work with Sir Philip Cohen, who was, at the time, the world’s third most cited professor.
David-Alexandre C. Gros
David-Alexandre C. Gros
Co-Founder and Chief Executive Officer of Imbria Pharmaceuticals
D.A. Gros, MD, MBA is Co-Founder and Chief Executive Officer of Imbria Pharmaceuticals. D.A. has extensive experience in building and financing bio-pharmaceutical companies as well as developing and executing growth strategies. He joined Eliem from Neurocrine Biosciences where he was President, Chief Operating Officer, and acting Chief Financial Officer. Prior to Neurocrine, he served as Chief Business Officer and Principal Financial Officer of Alnylam Pharmaceuticals, and as Chief Strategy Officer of Sanofi. Before joining Sanofi, D.A. held positions of increasing responsibility with a focus on biotechnology and pharmaceuticals in investment banking at Centerview Partners and Merrill Lynch, and in consulting at McKinsey & Company. He holds an MD from Johns Hopkins University School of Medicine, an MBA from Harvard Business School, and an AB from Dartmouth College.
Head of Access Biotechnology
Dr. Ratcliffe is the head of Access Biotechnology, the strategic investment arm specializing in therapeutic platforms and products at Access Industries. Prior to his work at Access Industries, he was Managing Director at New Leaf Venture Partners, where he concentrated on biopharmaceutical investing. Prior to joining New Leaf in 2008, Dr. Ratcliffe served as Senior Vice President and Development Head for Pfizer Neuroscience, as well as Worldwide Head of Clinical Research and Development. Additional positions during his 12 years at Pfizer included Vice President of Exploratory Development for the Midwest region (based in Ann Arbor, Mich.) and Head of Experimental Medicine at Pfizer’s Sandwich, UK Laboratories.
Dr. Ratcliffe received his M.D. and Ph.D. in Immunology from the University of Cape Town and his M.B.A. from the University of Michigan. He completed his internal medicine training and fellowship in Immunology at Groote Schuur Hospital and associated teaching hospitals in Cape Town, South Africa.
Contact us for more information: